ClinicalTrials.gg
CompletedNCT04220801Updated Apr 28, 2021

A Study of Orally Administered ZM-H1505R to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Doses in Healthy Participants

A Phase 1 interventional study of ZM-H1505R in Healthy Volunteers, sponsored by Shanghai Zhimeng Biopharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-28.

Sponsored by Shanghai Zhimeng Biopharma, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Nov 2020, 5 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

ZM-H1505R is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Chronic Hepatitis B.

The purpose of this study is to see how safe the study drug is and how well it is tolerated after dosing. The study will also test how the study drug is taken up and eliminated by the body. An additional part of the study is to look at how this could be changed by giving the study drug with food.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Shanghai Zhimeng Biopharma, Inc. is the lead sponsor of 11 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Are capable of giving and complying with study procedures;
    1. Are between the ages of 18 and 55 years, inclusive;
    1. Female subjects have a negative pregnancy test results at screening and Day -1, and meet one of the following criteria:

      1. Using a medically acceptable form of for at least 1 month prior to screening (3 months on oral contraceptives) [e.g., hormonal contraceptives (oral, patch, injectable or vaginal ring), implantable device (implantable rod or intrauterine device), or a double barrier (e.g., diaphragm, cervical cap, oral, patch or vaginal hormonal contraceptive, condom, spermicide, or sponge)]
      2. Surgically sterile for at least 3 months prior to screening by one of the following means:

        • Bilateral tubal ligation
        • Bilateral salpingectomy (with or without oophorectomy)
        • Surgical hysterectomy
        • Bilateral oophorectomy (with or without hysterectomy)
      3. , defined as the following:

        • Last menstrual period greater than 12 months prior to screening
        • Postmenopausal status confirmed by serum FSH and estradiol levels at screening;
    1. Considered healthy by the Investigator, based on subject's reported medical history, full PE, clinical laboratory tests, 12-lead , and vital signs;
    1. Normal liver function (/ALT \< 1.5x ) and normal renal function (> 60mL/min/1.73 m2) as determined by Investigator following review of clinical laboratory test results;
    1. Non-smoker and no nicotine containing products (including e-cigarettes) within 6 months;

      -- 7. (BMI) of 18.0 to 32.0 kg/m2 inclusive and body weight not less than 50 kg;

    1. Willing and able to adhere to study restrictions and to be confined at the clinical research center.
    1. Male subjects with female partners of child bearing potential must agree to use condoms for the duration of the study and until 12 weeks after dosing with the study drug and must refrain from donating sperm for this same period.

Exclusion criteria

Exclusion Criteria:

    1. history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug as determined by the Investigator;
    1. Reported or suspected ;
    1. Reported history of pancreatitis or gall stones;
    1. Reported history of unexplained syncope, symptomatic hypotension or hypoglycemia;
    1. Reported family history of long syndrome;
    1. Reported history of chronic diarrhea, malabsorption, unexplained weight loss, food allergies or intolerance;
    1. Poor venous access;
    1. Positive blood screen for (HIV), surface antigen (HBsAg), or antibody;
    1. Donated or lost >500ml of blood in the previous 3 months;
    1. Taken an drug or participated in a clinical trial within 3 months (or 5 half-lives), whichever is longer;
    1. Taken any prescription medications within 14 days or 5 half-lives (whichever is longer) of the first dose of study drug;
    1. Hospital admission or major surgery within 6 months prior to screening;
    1. A reported history of prescription drug abuse, or illicit drug use within 9 months prior to screening;
    1. A reported history of alcohol abuse according to medical history within 9 months prior to screening;
    1. A positive screen for alcohol, drugs of abuse at screening or Day -1;
    1. An unwillingness or inability to comply with food and beverage restrictions during study participation;
    1. Use of over-the-counter (OTC) medication within 7 days, and herbal supplements (including St John's Wort, herbal teas, garlic extracts) within 7 days prior to dosing (Note: Use of acetaminophen at \< 2 g/day is permitted until 24 hours prior to dosing)
    1. Any condition or finding that in the Investigators opinion would put the subject or study conduct at risk if the subject were to participate in the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Cohort 1 of Part 1 (SAD)

    300 mg ZM-H1505R or placebo

    Drug: ZM-H1505R

  • Experimental
    Cohort 2 of Part 1(SAD)

    450 mg ZM-H1505R or placebo

    Drug: ZM-H1505R

  • Experimental
    Cohort 3 of Part 1(SAD)

    150 mg ZM-H1505R or placebo (2 periods)

    Drug: ZM-H1505R

  • Experimental
    Cohort 4 of Part 1(SAD)

    75 mg ZM-H1505R or placebo

    Drug: ZM-H1505R

  • Experimental
    Cohort 5 of Part 1(SAD)

    25 mg ZM-H1505R or placebo

    Drug: ZM-H1505R

  • Experimental
    Cohort 1 of Part 2 (MAD)

    75 mg ZM-H1505R or placebo

    Drug: ZM-H1505R

  • Experimental
    Cohort 2 of Part 2 (MAD)

    150 mg ZM-H1505R or placebo

    Drug: ZM-H1505R

  • Experimental
    Cohort 3 of Part 2 (MAD)

    300 mg ZM-H1505R or placebo

    Drug: ZM-H1505R

Interventions

  • DrugZM-H1505R

    Single oral doses of 300, 450, 600, 750, and 900 mg of ZM-H1505R or placebo and multiple oral doses of 450, 600, and 750 mg of ZM-H1505R or placebo will be administered in a fasted state, or in the case of Cohort 3 (Part 1), a second dose of 600 mg will be administered in the fed state. During each SAD and MAD dosing period, 2 subjects in each cohort will receive placebo instead of ZM-H1505R. The dose levels may be adjusted based on the safety and tolerability obtained from the previous cohort.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events

    Safety data from subjects in Part 1 and Part 2 treated with placebo will be pooled, respectively. Safety evaluations will be based on the incidence, intensity, and relatedness of AEs

    Time frame: 22 days for Cohorts 1, 2, 4, and 5; 36 days for Cohort 3 in part 1 and Chorts in part 2

  2. Number of Participants With Abnormal Physical Examinations

    Safety data from subjects in Part 1 and Part 2 treated with placebo will be pooled, respectively. Safety evaluations will be based on the incidence, intensity, and relatedness of AEs and changes in subject PE findings

    Time frame: 22 days for Cohorts 1, 2, 4, and 5; 36 days for Cohort 3 in part 1 and Chorts in part 2

  3. Number of Participants With Abnormal Vital Signs

    Safety data from subjects in Part 1 and Part 2 treated with placebo will be pooled, respectively. Safety evaluations will be based on the incidence, intensity, and relatedness of AEs and changes in subject vital signs

    Time frame: 22 days for Cohorts 1, 2, 4, and 5; 36 days for Cohort 3 in part 1 and Chorts in part 2

  4. Number of Participants With Clinically Significant Laboratory Findings

    Safety data from subjects in Part 1 and Part 2 treated with placebo will be pooled, respectively. Safety evaluations will be based on the incidence, intensity, and relatedness of AEs and changes in subject clinical laboratory results

    Time frame: 22 days for Cohorts 1, 2, 4, and 5; 36 days for Cohort 3 in part 1 and Chorts in part 2

  5. Number of Participants With Abnormal ECGs

    Safety data from subjects in Part 1 and Part 2 treated with placebo will be pooled, respectively. Safety evaluations will be based on the incidence, intensity, and relatedness of AEs and changes in subject ECGs.

    Time frame: 22 days for Cohorts 1, 2, 4, and 5; 36 days for Cohort 3 in part 1 and Chorts in part 2

07

Study locations

1 site
  • Frontage Clinical Services
    Secaucus, New Jersey 07094, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Nov 2020, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2019
First posted
Jan 7, 2020
StartActual
Feb 17, 2020
Primary completionActual
Nov 18, 2020
CompletionActual
Nov 18, 2020
Last update
Apr 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04220801
Lead sponsor
Shanghai Zhimeng Biopharma, Inc.
Responsible party
Sponsor
First posted
Jan 7, 2020
Start date
Feb 17, 2020
Primary completion
Nov 18, 2020
Completion
Nov 18, 2020
Last update
Apr 28, 2021

Study contacts

Gregory Tracey, MD.
principal investigator · Frontage Clinical Services, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion